Inhibitors of Multidrug Resistance Transporter P-Glycoprotein
AssigneeSouthern Methodist University
InventorsJohn G. Wise, Pia D. Vogel, Frances K. Brewer, Courtney A. Follit
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method of treating a subject that is resistant to one or more drugs by identifying a subject having one or more drug resistant cells; administering to the subject a pharmaceutically effective amount of an inhibitor compound, and contacting one or more drug resistant cells with the inhibitor compound to reduce the export of the inhibitor compound from the one or more drug resistant tumor cells and to block the transport of drug(s) from the one or more drug resistant cells.
Claims20
A method of treating a subject having cancer that is resistant to one or more chemotherapeutic drugs comprising the steps of:
- identifying a subject having one or more drug resistant cancer cells that express a P-glycoprotein;
- administering to the subject a pharmaceutically effective amount of an inhibitor compound having one of the following structural formulas:
- contacting one or more drug resistant cancer cells with the inhibitor compound to reduce the drug resistance of the cancer cells.
A method of decreasing the P-glycoprotein activity of a cancer patient who has built up resistance to a therapeutically active agent used in the treatment of a cancer that expresses a P-glycoprotein to reduce the resistance to further treatment with the substance comprising the steps of:
- administering to a cancer patient before further treatment, during treatment or after treatment with the therapeutically active agent, an amount of an inhibitor compound having one of the following structural formulas:
- sufficient to reduce the export of the inhibitor compound and to block the transport of the therapeutically active agent from one or more cancer cells of the cancer patient.
A method of reducing the likelihood of developing a resistance to a therapeutically active agent comprising the steps of:
- administering to a patient before further treatment, during treatment or after treatment with the therapeutically active agent, an amount of an inhibitor compound having one of the following structural formulas:
- sufficient to reduce the export of the inhibitor compound and to block the transport of the therapeutically active agent from one or more cells of the patient.
A method for modulating the activity of a cell membrane transporter in a biologic tissue comprising the steps of:
- contacting a tissue having a cell membrane transporter with a pharmaceutically effective amount of an inhibitor compound having one of the following structural formulas:
A molecule having the formula:
Dependencies are inferred from the claim text.